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Increasingly, reverse transcriptase polymerase chain reaction (RT–PCR) is used to detect clinically signiﬁcant tumour cells in
blood or bone marrow. This may result in a redeﬁnition of disease-free and clinical relapse. However, its clinical utility may be
limited by lack of automation or reproducibility. Recent studies have suggested nucleic acid sequence-based ampliﬁcation of
target RNA may be more robust. In this study, nucleic acid sequence-based ampliﬁcation was established to detect melanoma,
colorectal and prostate cancer cells. Nucleic acid sequence-based ampliﬁcation and RT–PCR both successfully ampliﬁed target
RNA in peripheral blood samples from patients with melanoma and colorectal cancer, but only RT–PCR detected PSA in
blood samples from patients with prostate cancer. There was relatively good agreement between sample replicates analyzed
by RT–PCR (Kappa values of one for tyrosinase, 0.67 for CK-20 and one for PSA), but less agreement when analyzed by
nucleic acid sequence-based ampliﬁcation. This may limit the routine use of NASBA for the detection of clinically signiﬁcant
disease. In summary, RT–PCR appears at present to be the most reliable and reproducible method for the detection of low-
level disease in cancer patients, although prospective studies are warranted to assess the clinical utility of different molecular
diagnostic methods.
British Journal of Cancer (2002) 86, 102–109. DOI: 10.1038/sj/bjc/6600014 www.bjcancer.com
ã 2002 The Cancer Research Campaign
Keywords: RT–PCR; NASBA; minimal-disease; prostate; melanoma; colorectal
The dissemination of tumour cells in patients with solid cancer is a
necessary, but not sufﬁcient, factor in the process of metastasis.
Detection of dissemination is routinely used to assess the stage
of disease, and subsequently deﬁne the most appropriate treatment.
Consequently, sensitive and accurate methods for detection are
essential to increase understanding of the role clinical metastases
play in the progression of cancer, and their potential prognostic
signiﬁcance. Ultimately such methods will lead to a redeﬁnition
of what constitutes residual disease and clinical relapse, affecting
future patient outcome.
Increasingly, reverse transcriptase polymerase chain reaction
(RT–PCR) (Figure 1A) for tumour- or tissue-speciﬁc targets is
used to detect tumour cells in bone marrow, peripheral blood
and stem cell harvests with greater sensitivity than more conven-
tional methods (Johnson et al, 1995). There is now good
evidence that using this method it is possible to detect disease of
clinical signiﬁcance (Burchill and Selby, 2000; Burchill et al,
2001). Therefore RT–PCR may increase the power of minimal
residual disease and micro-metastatic disease detection in some
patients with cancer, which may result in a more accurate prog-
nosis and/or improved treatment timing or selection.
Although RT–PCR is very sensitive, its clinical utility may be
limited by lack of automation and reproducibility in clinical
samples, reﬂected in the conﬂicting literature and the number of
reported ‘false’ positives or negatives. Previous studies have shown
sample processing and the method of RNA extraction to signiﬁ-
cantly contribute to the sensitivity of RT–PCR (Keilholz et al,
1998; Burchill et al, 1999) although the question of false positive
or negative results has remained a challenge. It is clear even
patients with haematogenously disseminated disease do not invari-
ably have tumour cells in all bone marrow or peripheral blood
samples (Burchill and Selby, 2000). This has often been interpreted
as a ‘false negative’ result, although it most likely reﬂects features of
the metastatic disease process such as intermittent tumour-cell
shedding. This emphasises the need for quality-controlled, long-
term clinical outcome studies in which variables such as the
frequency of sampling and sample volume are evaluated. However,
false positive results remain a more technical concern. These are a
particular problem when the target mRNA is contaminated with
DNA, transcribed from a gene that lacks introns or where the
intron-exon boundaries of the target gene are unknown.
An alternative method of RNA ampliﬁcation, nucleic acid
sequence-based ampliﬁcation (NASBA), is reported to speciﬁcally
amplify RNA but not DNA (Heim et al, 1998). Since NASBA
ampliﬁes RNA using an RNA T7-polymerase promoter to gener-
ate multiple RNA products at 418C, double stranded DNA is
not denatured and consequently not ampliﬁed (Figure 1B)
(Chan and Fox, 1999; Simpkins et al, 2000). NASBA has tradi-
tionally been used for the ampliﬁcation of blood-borne viruses
(Kievits et al, 1991; van Gemen et al, 1993), though it may also
be useful for the detection of circulating tumour cells
(Lambrechts et al, 1998, 1999). Potentially NASBA has two
powerful advantages over RT–PCR for the molecular detection
of circulating tumour cells. Firstly, knowledge of the target gene
intron-exon boundaries is not essential, and secondly, contami-
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www.bjcancer.comnating DNA should not affect the efﬁciency and reproducibility
of ampliﬁcation. These advantages should make the design of
new ampliﬁcation methods for the detection of circulating
tumour cells less challenging, and improve the ampliﬁcation
efﬁciency in samples contaminated with DNA, which can be a
particular problem in clinical samples.
The aims of this study were: (1) to establish NASBA assays for
the detection of tumour cells; (2) compare the power of NASBA
and RT–PCR to detect a mRNA target in total RNA or mixed
nucleic acids (DNA/RNA); and (3) evaluate the sensitivity and
speciﬁcity of circulating tumour cell detection by NASBA and
RT–PCR using an in vivo model system and clinical samples.
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Figure 1 Schematic representation of methods for the ampliﬁcation of mRNA using (A) NASBA, and (B) RT–PCR.
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Cell lines
Three tumour cell lines were used to develop the NASBA assay; the
colonic adenocarcinoma HT-29 (cultured in 50:50 DMEM:RPMI,
5% FCS), prostate carcinoma LNCAP (RPMI, 10% FCS) and
malignant melanoma derived SKmel 23 (50:50 DMEM:RPMI,
10% FCS) (Table 1).
Six tumour cell lines were used as controls; the neuroblastoma
cell lines SK-N-SH (50:50 DMEM:EMEM, 10% FCS) and IMR-
32 (RPMI:DMEM, 10% FCS), the Ewing’s sarcomas RD-ES and
TC-32 (RPMI, 10% FCS), the rhabdomyosarcoma SJRH-30
(DMEM:RPMI, 10% FCS) and the breast carcinoma MCF-7
(DMEM, 10% FCS). Cell lines were maintained at 378Ci n
5%CO2:95% air. All cell lines were purchased from the American
Type Culture Collection, with the exception of the SKmel 23 cells
that were a gift from Professor I Hart, Richard Dimbleby and ICRF
Department of Cancer Research, St Thomas’s Hospital, London.
Extraction of total RNA
Total RNA was isolated using Ultraspec
TM RNA (Biogenesis, Bour-
nemouth, UK), as previously described (Burchill et al, 1994). The
purity and quantity of recovered RNA was measured by reading
the optical density at 260 and 280 nm. The quality of RNA was
conﬁrmed by separation of RNA (1 mg) in a 16 TBE agarose
gel and staining with ethidium bromide (0.5 mgm l
71) before
visualization under UV light, and by RT–PCR ampliﬁcation for
the ubiquitously expressed house-keeping gene, b2 microglobulin
(see below).
Extraction of nucleic acids (DNA/RNA)
Nucleic acids (DNA/RNA) were extracted from cell lines using the
method of Boom et al. (1990). At room temperature cells were
added to 5 M guanidinium isothiocyanate, mixed and 50 ml of sili-
ca slurry added. Samples were incubated with silica for 10 min at
room temperature, vortexing two or three times during this incu-
bation. Silica was isolated by centrifugation for 15 s613000 g, and
the supernatant discarded. Silica was washed twice in 950 mlo f
guanidinium isothiocyanate, twice in 950 ml of 70% ethanol and
once in 900 ml of acetone. Silica was heated at 568C for 10 min
to dry, and subsequently the DNA/RNA was eluted in 50 mlo f
double distilled RNAse-free water by heating at 568C for 10 min.
The silica was isolated by centrifugation for 1 min at 13000 g
and the supernatant containing nucleic acids removed. This nucleic
acid (DNA/RNA) mix was centrifuged a second time to remove
any residual silica prior to nucleic acid spiking experiments.
Reverse transcriptase polymerase chain reaction
Reverse transcriptase polymerase chain reaction was performed for
CK-20, tyrosinase, PSA and b2 microglobulin using primers designed
to amplify across an intron/exon boundary (Table 1) as previously
described (Burchill et al, 1994). Brieﬂy, RNA (in 5 ml of depc treated
water) was heated to 958C for 5 min and rapidly cooled on ice. Reac-
tion mix (5 ml) was added to the RNA to give ﬁnal concentrations of
16 PCR buffer (50 mM KCl, 10 mM Tris HCl, pH 8.3), 1 mM dATP,
dCTP, dGTP and dTTP (Pharmacia, Uppsala, Sweden), 8 mM
MgCl2, 15 ng random hexamer primers (Gibco BRL), 20 U RNA
guard (Pharmacia) and 5 U murine moloney leukaemia virus reverse
transcriptase (Pharmacia). After incubation at 378C for 1 h the
samples were heated to 958C for 5 min to destroy the reverse tran-
scriptase (RT) activity. After cooling on ice, 40 ml of PCR mix (16
PCR buffer as above, 2.5 U Amplitaq Gold (Perkin Elmer) and
25–50 mM of each primer (Table 1)) were added to the RT products,
mixed and overlaid with mineral oil.
Tyrosinase was ampliﬁed by denaturation at 958C for 1 min,
annealing at 558C for 1 min and extension at 728C for 1 min for
50 cycles, CK-20 and PSA mRNA were ampliﬁed under the same
conditions except the annealing temperature was increased to
608C. A ﬁnal extension for 10 min at 728C was performed for each
target. To ensure that only RNA was ampliﬁed, a negative control
in which the RT enzyme was omitted was performed for each
sample. After ampliﬁcation, the PCR products were separated by
electrophoresis in a 2% agarose gel, stained with ethidium bromide
(0.5 mgm l
71) and visualized under UV light. The identity of
ampliﬁed products was initially conﬁrmed by direct sequence
analysis, and by Southern blotting in subsequent experiments.
Primers for RT–PCR were purchased from the Imperial Cancer
Research Fund, Lincoln’s Inn Fields, London.
Nucleic acid sequence-based ampliﬁcation
Nucleic acid sequence-based ampliﬁcation assays were established
using cell line RNA at the laboratories of Organon Teknika (Boxtel,
The Netherlands). Brieﬂy, multiple primer and probe sets for each
of the mRNA targets were developed and tested in serial dilutions
of cell line RNA. The optimal KCL concentration and amplicon
dilution factors were determined individually for each target. In
these optimization studies ampliﬁed products were Northern
blotted and hybridized with
32P-labelled probes; the best primer/
probe combination was used to develop the NASBA ECL detection
assay (Table 2). All subsequent experiments were carried out in
Leeds using these optimized conditions.
Brieﬂy, RNA (in 5 ml) was added to 10 ml of NASBA buffer and
pre-incubated at 658C for 5 min before incubation at 418C for
5 min. Enzyme mix (5 ml; 0.08 U E.coli RNase H, 32 U T7-RNA
polymerase, 6.4 U avian myeloblastosis virus RT) was added and
the reaction was incubated at 418C for 90 min. The ﬁnal concen-
trations in the NASBA buffer were 40 mM Tris HCl pH 8.5,
12 mM MgCl2,7 0 m M KCl, 5 mM dithiothreitol, 15% dimethyl
sulphoxide, 1 mM of each dNTP, 2 mM of ATP, CTP and UTP,
1.5 mM GTP, 0.5 mM ITP and 10 pM of each primer. Primer sets
used for ampliﬁcation are shown in Table 2.
A semi-automated electro-chemiluminescense system (NASBA
QR) was used to detect amplicons. Products were diluted and
hybridized with two probes complementary to the ampliﬁed
RNA sequence in pre-mix (Table 2). The biotinylated capture
probe is immobilized onto streptavidin coated paramagnetic beads,
and the ECL probe is labelled with ruthenium ester, the ﬂuores-
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Table 1 Cancer cell lines and primers used for ampliﬁcation of target mRNA using RT–PCR
Cell Target mRNA Predicted
Cancer line for ampliﬁcation Sense primer Antisense primer product size
Colorectal HT-29 CK-20 CAGACACACGGTGAACTATGG GATCAGCTTCCACTGTTAGACG 370 bp
Melanoma SKmel 23 Tyrosinase GTCTTTATGCAATGGAACGC GCTATCCCAGTAAGTGGACT 207 bp
Prostate LNCAP PSA ACACAGGCCAGGTATTTCAG CCTTGAAGCACACCATTACA 420 bp
b2 microglobulin CTCGCGCTACTCTCTCTTTCT TGTCGGATTGATGAAACCCAG 136 bp
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1 ECL reader (Organon
Teknika). The pre-mix contained 10 ml of 0.05 mg beads and
0.084 mM of biotinylated capture probe in 16 PBS and 0.1%
BSA, and 10 ml of 0.05 mM ruthenium probe in 5 g l
71 2-chloro
acetamide, 0.1% BSA and 12.56 SSC. The optimum dilution of
ampliﬁed products and temperature of annealing are different for
each target. For CK-20 and tyrosinase the optimum dilution factor
is 1:16, for PSA 1:2; annealing was performed at 508C, 418C and
608C respectively.
A proprietary reference positive control was included in each
assay, along with a hybridization assay negative control (consisting
of the two probes with water instead of the ampliﬁcation reaction
components). The hybridization negative control was used to
deﬁne a cut-off for ECL readings; any reading 10 times greater than
the negative control value was taken as positive. The probes and
primers for NASBA were synthesized and puriﬁed by Organon
Teknika.
In vitro sensitivity, speciﬁcity and reproducibility
The sensitivity of NASBA and RT–PCR for the detection of target
mRNA in a background of total RNA or total nucleic acids was
evaluated by diluting RNA or nucleic acids (DNA/RNA) from
HT-29 cells (which express CK-20 mRNA), in either total RNA
or nucleic acids (DNA/RNA) from a cell line that does not express
CK-20 mRNA (SK-N-SH). RNA (0–1 ng, extracted using Ultra-
spec
TM) or DNA/RNA (0–1 ng, isolated using the Boom
method) from HT-29 cells was added to RNA (5 mg) or DNA/
RNA (5 mg) extracted from the neuroblastoma cell line SK-N-SH.
These spiked samples were prepared and analyzed for CK-20
mRNA by NASBA and RT–PCR three times. Data was analyzed
using exact logistic regression (Mehta and Patel, 1995).
The sensitivity, speciﬁcity and reproducibility of NASBA and
RT–PCR for the detection of CK-20, PSA and tyrosinase mRNA
were subsequently evaluated using RNA spiking experiments.
RNA (0–100 ng) extracted from HT-29, LNCAP and SKmel
23 cells using Ultraspec
TM, was added to 5 mg of RNA extracted
from normal peripheral blood of volunteers. Parallel samples were
analyzed for CK-20, PSA or tyrosinase mRNA in six separate
experiments. The reproducibility of, and agreement between
NASBA and RT–PCR were assessed by calculating the Kappa
statistic (Altman, 1991). The Kappa statistic represents the level
of agreement observed over and above that expected by chance.
It is deﬁned as (Probability observed7Probability expected) 
(1 – Probability expected). It can vary between 71 and +1, with
0 representing no agreement over that expected by chance. A high
level of agreement is usually indicated by a Kappa of approximately
0.7 or above.
Clinical samples
Blood samples were collected from patients with melanoma
(n=12), colon (n=12) or prostate cancer (n=12) attending the ICRF
Medical Oncology Unit, St James’s University Hospital, Leeds or
Cookridge Hospital, Leeds. Normal control blood samples (n=8)
were taken from healthy volunteers. All blood samples (2 ml) were
collected into 20 mM EDTA, mixed and 8 ml of Ultraspec
TM
(Biogenesis, Bournemouth, UK) added. Samples were stored at
7808C until required for RNA extraction. Each RNA sample was
divided and equivalent to 1 mg of RNA analyzed by NASBA or
RT–PCR. All patients and volunteers from whom blood was taken
gave informed consent.
RESULTS
NASBA assay for CK-20, PSA and tyrosinase
A NASBA assay was established for the speciﬁc detection of CK-20,
PSA and tyrosinase mRNA in RNA extracted from HT-29, LNCAP
and SKmel-23 cells respectively (Figure 2). Target mRNA was not
detected in RNA from control cell lines, or in RNA extracted from
peripheral blood of healthy volunteers. Using NASBA it was possi-
ble to detect CK-20 mRNA in 10 pg of total RNA from HT-
29 cells, and PSA and tyrosinase mRNA in 1 pg of LNCAP and
SKmel 23 RNA respectively (Figure 2).
Sensitivity of NASBA and RT–PCR for the detection of
CK-20 mRNA in isolated RNA and nucleic acids
(DNA/RNA)
The detection of CK-20 mRNA (1000 pg of HT-29 RNA) diluted
in unrelated RNA or nucleic acids (DNA/RNA) by RT–PCR or
NASBA was equally sensitive (24 out of 24 positive) (Table 3).
Furthermore both NASBA and RT–PCR were equally speciﬁc, 0
out of 24 tests were positive for CK-20 mRNA when no target
mRNA was added. The addition of 5 mg of RNA or nucleic acids
isolated from SK-N-SH cells, which do not express CK-20 mRNA,
did not affect the speciﬁcity of ampliﬁcation (P40.5, results not
shown). Therefore the ampliﬁcation results for CK-20 mRNA
detection by NASBA or RT–PCR in the presence of SK-N-SH
derived RNA or nucleic acids have been pooled (Table 3).
However, the number of samples positive for CK-20 mRNA (8
out of 12) detected in HT-29 RNA diluted in total RNA was signif-
icantly higher than the number of positives detected in nucleic
acids (DNA/RNA) (for 10 pg of HT-29 RNA P50.001 odds ratio
32.4, 95% CI 3.6–inﬁnity and for 100 pg of HT-29 RNA P=0.004
odds ratio 7.0, 95% CI 0.4–471.1 respectively) (Table 3).
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Table 2 PrimersandprobesusedfortheampliﬁcationanddetectionoftargetmRNAusingNASBA.TheT7promotersequenceisunderlined
Target mRNA Predicted
for ampliﬁcation Primer or probe description Sequence 5'–3' product size
CK-20 CK-20 Northern probe AGAGGAGACCAAGGCCCGTTA
P1A AATTCTAATACGACTCACTATAGGGAGAAGGCGGCGGTAAGTAGCA 210 bp
P2A ATGAAAGAGTCTTTGGAGCA
ECL probe AGCAGCCAGTTAGCCAACCTCCA
Capture probe GATCTTGCTGGGTCGGCAC
Tyrosinase P1B AATTCTAATACGACTCACTATAGGGAGAAGGATATTCTGACAGGA 145 bp
P2B TTCCAGACCTCCGCTGGCCA
ECL probe TCTAAGAACCTGATGGAGAAGG
Capture probe TTCCCTAGAGCCTGTGTCTCC
PSA P1C AATTCTAATACGACTCACTATAGGGAGGAGGCTCATATCGTAGA 193 bp
P2C TGGCCTCTCGTGGCAGGGCA
ECL probe TTCATCCTGAAGACACAGGC
Capture probe CTTGCTGGGTCGGCACAGCC
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mRNA in 6 out of 12 samples compared to 2 out of 12 detected by
NASBA (P=0.06), odds ratio 7.6 (95% CI 0.8–inﬁnity); whereas at
100 pg of HT-29 RNA RT–PCR detected 10 out of 12 positive
samples compared to 7 out of 12 for NASBA (P=0.20, odds ratio
7.0 (95% CI 0.4–471.1) (Table 3).
Sensitivity and reproducibility of NASBA and RT–PCR
assays for detection of CK-20, PSA and tyrosinase mRNA
In vitro cell assay The sensitivity of NASBA for the detection of
tumour cell derived target mRNA is similar to that achieved with
RT–PCR, the absolute sensitivity of either assay varying depending
on the target mRNA species. The maximum sensitivity for the
detection of CK-20 mRNA by NASBA was comparable to that
for its detection by RT–PCR (Table 4). However the NASBA assay
for the detection of PSA was an order of magnitude more sensitive
than RT–PCR, whereas the NASBA assay for tyrosinase was an
order of magnitude less sensitive than RT–PCR (Table 4). The
maximum sensitivity range for NASBA or RT–PCR for all three
mRNA targets in the cell lines used was between 100 fg and 10 ng.
Patient blood samples NASBA and RT–PCR both successfully
ampliﬁed target mRNA in peripheral blood from patients with
melanoma and colorectal cancer (Table 5). However NASBA failed
to detect PSA mRNA, detected by RT–PCR, in peripheral blood
from two patients with prostate cancer (Table 5).
There was good agreement between sample replicates analyzed
by RT–PCR for tyrosinase, CK-20 or PSA mRNA, as demonstrated
by the Kappa values of 1, 0.67 and 1 respectively (Table 5).
However replicates analyzed by NASBA for tyrosinase or CK-20
mRNA showed no statistical agreement (Table 5). PSA mRNA
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Figure 2 Ampliﬁcation of (i) CK-20; (ii) tyrosinase; and (iii) PSA mRNA in total RNA extracted from HT-29, SKmel 23 and LNCAP cell lines respectively
using NASBA (A) and RT–PCR (B). A histogram showing the ECL read-outs for NASBA, and RT–PCR products separated in an agarose gel, stained with
ethidium bromide and visualized under UV light are shown. The identity of RT–PCR ampliﬁed products was conﬁrmed by both Southern blot and direct
sequence analysis (results not shown).
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patients with prostate cancer (Table 5). Since both observed agree-
ment proportions and expected agreement proportions were equal
to 1, the Kappa (agreement above that expected by chance) is
either 0 or undeﬁned; providing little information on the expected
level of agreement.
There was no statistical agreement, beyond chance, between the
presence of CK-20, tyrosinase or PSA mRNA in peripheral blood
when analyzed by NASBA and RT–PCR. This is not so surprising
given the lack of agreement between replicates analyzed by NASBA
(Table 5).
DISCUSSION
NASBA can be used to detect mRNA transcripts in tumour cell
lines to a sensitivity equal to that detected by RT–PCR. The sensi-
tivity of both methods is target dependent, and requires careful
primer design and assay optimization. All the assays used in this
study were speciﬁc, and did not amplify unrelated RNA’s in either
control blood samples or control tumour cell lines. However,
during the development of the NASBA assay for CK-20 and tyro-
sinase mRNA primer sets used within a single exon ampliﬁed target
products in whole blood and human placental nucleic acids (results
not shown). The development of both NASBA and RT–PCR assays
required knowledge of the gene sequences and their intron-exon
boundaries, allowing design of primers that amplify across introns
to prevent generation of products from contaminating DNA.
Previous studies have suggested the nucleic acid isolation proce-
dure has no inﬂuence on the ampliﬁcation by NASBA (van
Gemen et al, 1995; Chan and Fox, 1999; Simpkins et al, 2000),
however when used to detect low copy number this clearly
becomes a signiﬁcant factor.
The clinical application of RT–PCR or NASBA for the detection
of circulating tumour cells requires a reliable and reproducible
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Table 3 Effect of unrelated RNA or nucleic acids (DNA/RNA) on the detection of CK-20 mRNA by RT–PCR or
NASBA. RNA or nucleic acids isolated from HT-29 cells were diluted in RNA or nucleic acids isolated from SK-N-SH
cells; the sensitivity of NASBA or RT–PCR for the detection of HT-29 mRNA (0–1000 pg) in the presence of SK-N-
SH RNA or nucleic acids were the same and are given in the text. Results for the detection of CK-20 mRNA in 10 or
100 pg of HT-29 mRNA are shown. Statistical signiﬁcance was evaluated using an exact logistic regression analysis
Amount of RNA
or nucleic acids
isolated from HT-29
cells in pg, added to
RNA or nucleic
acids (5 mg) from
SK-N-SH cells
RNA or nucleic
acids isolated
from HT-29
cells, added to
RNA or nucleic
acids isolated
from SK-N-SH cells
Number of positive scores/
number of tests each assay;
proportion (95% CI)
Number of positive
scores/number of tests in
RNA or nucleic acids;
proportion (95% CI) NASBA RT–PCR
10 pg HT-29 RNA 2/6 6/6 8/12; 0.66 (0.35–0.90)
HT-29 nucleic acids 0/6 0/6 0/12; 0 (0–0.27)
c
Pooled total 2/12; 0.17 6/12; 0.5
a 8/24; 0.33 (0.16–0.55)
(0.02–0.48) (0.21–0.79)
100 pg HT-29 RNA 6/6 6/6 12/12; 1 (0.74–1)
HT-29 nucleic acids 1/6 4/6 5/12; 0.42 (0.15–0.72)
d
Pooled total 7/12; 0.58 10/12; 0.83
b 17/24; 0.71 (0.53–0.89)
(0.28–0.85) (0.52–0.98)
aRT–PCR compared to NASBA: P=0.06 odds ratio=7.6 (0.8–inﬁnity).
bRT–PCR compared to NASBA: P=0.20 odds ratio=7.0 (0.4–
471.1).
cHT-29 RNA compared to HT-29 nucleic acids: P50.001 odds ratio 32.4 (3.6–inﬁnity).
dHT-29 RNA compared to HT-29
nucleic acids: P50.004 odds ratio 19.1 (2.3–inﬁnity).
Table 4 Sensitivity and reproducibility of NASBA and RT–PCR for the detection of CK-20, PSA and tyrosinase mRNA isolated from cell lines diluted in
total RNA (5 mg) isolated from peripheral blood from volunteers
RNA added 0 100 fg 1 pg 10 pg 100 pg 1 ng 10 ng 100 ng
CK-20 NASBA 1 0/6 N/A 0/6 3/6 5/6 6/6 6/6 6/6
2 0 0 0.50 0.83 1.00 1.00 1.00
3 0.00–0.46 0.00–0.46 00.12–0.88 0.36–1.00 0.54–1.00 0.54–1.00 0.54–1.00
RT–PCR 1 0/6 0/6 0/6 6/6 6/6 5/6 6/6 3/3
2 0 0 0 1.00 1.00 0.83 1.00 1.00
3 0.00–0.46 0.00–0.46 0.00–0.46 0.54–1.00 0.54–1.00 0.36–1.00 0.54–1.00 0.29–1.00
PSA NASBA 1 0/3 N/A 6/6 6/6 6/6 6/6 6/6 3/3
2 0 1.00 1.00 1.00 1.00 1.00 1.00
3 0.00–0.71 0.54–1.00 0.54–1.00 0.54–1.00 0.54–1.00 0.54–1.00 0.29–1.00
RT–PCR 1 0/3 0/3 0/3 6/6 6/6 6/6 6/6 3/3
2 0 0 0 1.00 1.00 1.00 1.00 1.00
3 0.00–0.71 0.00–0.71 0.00–0.71 0.54–1.00 0.54–1.00 0.54–1.00 0.54–1.00 0.29–1.00
Tyrosinase NASBA 1 0/4 0/6 2/6 6/6 6/6 6/6 6/6 3/3
2 0 0 0.33 1.00 1.00 1.00 1.00 1.00
3 0.00–0.60 0.00–0.46 0.04–0.78 0.54–1.00 0.54–1.00 0.54–1.00 0.54–1.00 0.29–1.00
RT–PCR 1 0/3 4/6 6/6 6/6 6/6 5/6 6/6 3/3
2 0 0.67 1.00 1.00 1.00 0.83 1.00 1.00
3 0.00–0.71 0.22–0.96 0.54–1.00 0.54–1.00 0.54–1.00 0.36–1.00 0.54–1.00 0.29–1.00
1=number of positive tests/number of tests performed, 2=proportion of positive results (number of positive testsnumber of tests performed), 3=95% conﬁdence intervals.
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(410 ng) both assays are reliable and reproducible when analyzing
target cell RNA spiked samples, at lower dilutions (1:5610
7 or
1:5610
6) the assays become less robust. This suggests detection
of tumour derived RNA is at the limits of the assay sensitivity,
consequently it is not surprising that the reproducibility between
replicates is not consistent at these low levels. However analysis
of blood samples from patients with melanoma or colorectal cancer
by NASBA was less informative than analysis by RT–PCR.
Furthermore, NASBA failed to detect tumour cells in blood
samples from patients with advanced prostate cancer, although
by RT–PCR two of the blood samples analyzed were positive.
The lack of concordance between duplicates when analyzed by
NASBA indicates the difﬁculties in assessing this assay at the limits
of detection. It would appear from the current study RT–PCR is
more robust than NASBA for the detection of low-level target
RNAs.
The sensitivity of both NASBA and RT–PCR was increased
when CK-20 mRNA was detected in isolated RNA rather than
isolated nucleic acids (DNA/RNA). This is not surprising as the
amount of CK-20 mRNA in 10 pg of puriﬁed RNA will be greater
than in 10 pg of nucleic acid (DNA/RNA). Previous studies have
shown the method of processing samples affects the sensitivity of
target gene detection by RT–PCR (Burchill and Selby, 2000), it
would appear this may also be the case with NASBA. Interestingly
the sensitive detection of viral RNA by NASBA is usually carried
out on total nucleic acids (van Gemen et al, 1995; Damen et al,
1999; Fiscus et al, 2000). Whether detection of viral RNA would
be more sensitive if RNA was puriﬁed is not clear. When target
RNA is abundant the method of sample processing is less critical,
however at the limits of detection puriﬁcation of RNA prior to
assay may be beneﬁcial.
Analysis of amplicons using NucliSens
1, like realtime RT–PCR
(Lie and Petropoulos, 1998; Bremer et al, 2000), has the advantage
over more traditional read-outs that sequence speciﬁc probes are
used to detect ampliﬁed products. Consequently the identity of
ampliﬁed products is conﬁrmed without the need for additional
steps (such as Northern blot). The products of NASBA can also
be analyzed in a quantitative way using a NucliSens
1 reader and
internal standards (van Gemen et al, 1995; Bustin, 2000), however
the NucliSens
1 reader detects ampliﬁed products at an end-point
unlike real-time PCR that detects products as they are generated.
Although both methods can be used to quantify the number of
RNA transcripts per sample, neither accurately reﬂects cell number
since the number of target RNA molecules per tumour cell is not
known. With increased knowledge of RNA transcripts per tumour
cell it may be possible to use such methods to assess cell number.
This is likely to be more informative within an individual than
between patients, as the level of RNA transcripts per cell varies.
However, changes in gene transcription (induced by such factors
as chemotherapy) may limit this (Burchill, unpublished observa-
tions).
In summary, NASBA can be used to detect low-levels of
tumour-derived target RNA. However despite the single tube
approach and semi-automation, lack of reproducibility currently
limits its potential application for the detection of clinically rele-
vant disease in patients with cancer. Ampliﬁcation of tumour
RNA in peripheral blood by RT–PCR currently appears to be
the most reproducible method for the detection of low-level disease
in cancer patients. However this method is labour intensive, and
would beneﬁt from the development of an automated procedure
that could be used in clinical outcome studies.
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Table 5 Comparison of tumour cell detection in patient blood samples. Statistical analysis has been performed on
patient blood samples analyzed by RT–PCR and NASBA using the Kappa statistic to test for agreement between
(A) replicates of the same blood sample analyzed by RT–PCR or NASBA, and (B) the two assays, RT-PCR and NAS-
BA, analyzing the same replicates
A. Agreement between replicates B. Agreement between assays
Replicate 2 NASBA
Test Replicate 1 Pos Neg Replicate RT–PCR Pos Neg
Melanoma
(Tyrosinase)
RT–PCR Pos
Neg
Kappa (CI)
6
0
1.00
0
6
(1.00–1.00)
1 Pos
Neg
Kappa (CI)
4
1
0.50
2
5
(0.02–0.98)
NASBA Pos
Neg
Kappa (CI)
3
2
0.31
2
5
(70.23–0.86)
2 Pos
Neg
Kappa (CI)
2
3
70.17
4
3
(70.72–0.38)
Colorectal
(CK-20)
RT–PCR Pos
Neg
Kappa (CI)
4
0
0.67
2
6
(0.27–1.00)
1 Pos
Neg
Kappa (CI)
2
0
0.33
4
6
(70.06–0.73)
NASBA Pos
Neg
Kappa (CI)
1
2
0.25
1
8
(70.37–0.87)
2 Pos
Neg
Kappa (CI)
2
1
0.40
2
7
(70.15–0.95)
Prostate
(PSA)
RT–PCR Pos
Neg
Kappa (CI)
2
0
1.00
0
10
(1.00–1.00)
1 Pos
Neg
Kappa (CI)
0
0
0.00
2
10
NASBA Pos
Neg
Kappa (CI)
0
0
0.00
0
12
2 Pos
Neg
Kappa (CI)
0
0
0.00
2
10
Pos=positive (target mRNA detected); Neg=negative (target mRNA not detected); CI=95% conﬁdence intervals.
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